Pascal Bamford - Akoya Biosciences Research President
| AKYADelisted Stock | USD 1.29 0.00 0.00% |
President
Pascal Bamford is Research President of Akoya Biosciences
| Age | 52 |
| Phone | 855 896 8401 |
| Web | https://www.akoyabio.com |
Pascal Bamford Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pascal Bamford against Akoya Biosciences stock is an integral part of due diligence when investing in Akoya Biosciences. Pascal Bamford insider activity provides valuable insight into whether Akoya Biosciences is net buyers or sellers over its current business cycle. Note, Akoya Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Akoya Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pascal Bamford over two months ago Disposition of 670 shares by Pascal Bamford of Akoya Biosciences at 1.25 subject to Rule 16b-3 | ||
Pascal Bamford over three months ago Disposition of 2567 shares by Pascal Bamford of Akoya Biosciences at 1.63 subject to Rule 16b-3 | ||
Pascal Bamford over six months ago Disposition of 25000 shares by Pascal Bamford of Akoya Biosciences at 12.3 subject to Rule 16b-3 | ||
Pascal Bamford over six months ago Disposition of 50000 shares by Pascal Bamford of Akoya Biosciences at 5.35 subject to Rule 16b-3 |
Akoya Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1749) % which means that it has lost $0.1749 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.5427) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Akoya Biosciences currently holds 84.15 M in liabilities with Debt to Equity (D/E) ratio of 0.62, which is about average as compared to similar companies. Akoya Biosciences has a current ratio of 3.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Akoya Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Gael Touya | AptarGroup | 55 | |
| Xiangwei Gong | AptarGroup | 55 | |
| Marc Prieur | AptarGroup | 59 | |
| Chad Campbell | AngioDynamics | 54 | |
| Robert Kuhn | AptarGroup | 63 | |
| Warren Nighan | AngioDynamics | 56 | |
| Pratik Shah | Design Therapeutics | 55 | |
| Hedi Tlili | AptarGroup | 50 | |
| Eldon Schaffer | AptarGroup | 53 | |
| Benjamin Davis | AngioDynamics | 61 | |
| David Helsel | AngioDynamics | 60 | |
| Kim Seabury | AngioDynamics | 58 | |
Management Performance
| Return On Equity | -3.54 | ||||
| Return On Asset | -0.17 |
Akoya Biosciences Leadership Team
Elected by the shareholders, the Akoya Biosciences' board of directors comprises two types of representatives: Akoya Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akoya. The board's role is to monitor Akoya Biosciences' management team and ensure that shareholders' interests are well served. Akoya Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akoya Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Clifford Hoyt, VP Affairs | ||
| Brian McKelligon, CEO President | ||
| CFA CFA, Secretary | ||
| Marilee MBA, Chief Officer | ||
| Jennifer Kamocsay, General Counsel | ||
| Nikolay Samusik, CoFounder | ||
| Pascal Bamford, Research President | ||
| Anthony Catalano, Senior Operations | ||
| Niroshan Ramachandran, Chief Officer | ||
| Priyam Shah, Senior Strategy | ||
| JD CFA, Secretary | ||
| Niro Ramachandran, Chief Officer | ||
| Yury Goltsev, CoFounder | ||
| Joseph Driscoll, Chief Officer | ||
| John Ek, Principal CFO | ||
| Garry Nolan, Independent CoFounder | ||
| Paul Grass, Senior Sales | ||
| Frederic Pla, Chief Officer | ||
| John CPA, Principal CFO |
Akoya Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akoya Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.54 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.80) % | ||||
| Current Valuation | 120.62 M | ||||
| Shares Outstanding | 49.95 M | ||||
| Shares Owned By Insiders | 72.58 % | ||||
| Shares Owned By Institutions | 69.79 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Book | 6.45 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Akoya Stock
If you are still planning to invest in Akoya Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Akoya Biosciences' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |